Semaglutide week by week
Reviewed 8 sourcesPublished by PepVault
What to expect on semaglutide week by week: the Wegovy label's dose steps, what the STEP trials saw at each stage, appetite, side effects and the plateau.

- Last reviewed
- Sources
- 8
- Questions
- 9
- Compounds
- 1
The short answer
Semaglutide, sold as Wegovy for weight, is a once-weekly injection. The label starts at 0.25 mg and steps up every four weeks, through 0.5, 1 and 1.7 mg, to 2.4 mg from week 17; a step that is not tolerated can wait four more weeks. Expect nausea around the step-ups that mostly fades, and loss that builds to about week 60: STEP 1 averaged 14.9% at 68 weeks.
Evidence: Randomised trials in people (STEP 1, 4 and 5, the phase 3b STEP UP, the SELECT outcomes trial and a 20-week appetite trial), the STEP 1 off-treatment extension, and the FDA label for Wegovy; semaglutide is FDA-approved, and the brain-distribution finding comes from animal studies.

How does semaglutide work?
Semaglutide is a copy of GLP-1, a hormone the gut releases after a meal, built to match the natural hormone at 94% of its sequence1. GLP-1 is one of the body's own regulators of appetite and of how much is eaten, and its receptor sits in several brain areas that set appetite. In animal studies, semaglutide reached those brain regions and switched on their neurons1. In people, the label says it cuts calorie intake, most likely through appetite, and it slows how fast the stomach empties1. The weight lost is more fat than lean mass1.
It lasts a week. A fatty acid fixed to the peptide lets it ride on albumin, a protein in the blood, which shields it and gives it a half-life of about one week1. Half-life is the time the body takes to clear half of a dose, so the level builds with each weekly dose before it settles. The same long tail means semaglutide is still in the blood for about five to seven weeks after the last injection1. Exposure rises in proportion to the dose1. The chart shows that build-up.
Try it
How Semaglutide builds up
An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.

What doses does the Wegovy label use?
The Wegovy label starts at 0.25 mg once a week and climbs in four-week steps: 0.5 mg in weeks 5 to 8, 1 mg in weeks 9 to 12 and 1.7 mg in weeks 13 to 16. From week 17 comes the maintenance dose, which for weight is 1.7 mg or the recommended 2.4 mg. The label sets this slow climb to lower the risk of stomach side effects, and if a step is not tolerated it suggests delaying the next one by four weeks1.
The current label adds a higher option. For adults who have tolerated 2.4 mg for at least four weeks and need more weight loss, the dose may go up to a maximum of 7.2 mg a week1. STEP 1, the main obesity trial, used the standard climb, reaching 2.4 mg after 16 weeks of escalation6.
These are the label's and the trials' schedules. The label leaves the maintenance dose to the prescriber, weighing response and tolerability1. They describe what was approved and studied, not a dose for any one person.
What happens week by week?
The table follows the label's standard climb to 2.4 mg and lines it up with what the trials measured. Weight loss is the average change from starting weight; in STEP 1, people started at about 105 kg1.
| Weeks | Label dose step | What the label and trials show |
|---|---|---|
| 1–4 | 0.25 mg | The starting dose. The slow climb is there to lower the risk of stomach side effects1. |
| 5–8 | 0.5 mg | The first step-up1. |
| 9–12 | 1 mg | The second step-up1. |
| 13–16 | 1.7 mg | The third step-up, and the lower of the two weight maintenance doses1. |
| 17 onward | 2.4 mg | The recommended maintenance dose. STEP 1 reached it after 16 weeks of escalation6. |
| Week 20 | Maintenance | STEP 4: people who reached 2.4 mg by the end of the 20-week run-in had lost 10.6% on average3. In a 20-week appetite trial of 72 adults: down 9.9%, against 0.4% on placebo4. |
| Around week 60 | Maintenance | The average weight loss levels off: in STEP 5 it plateaued after about week 60, as it appeared to in the 68-week trials5. |
| Week 68 | Maintenance | STEP 1: down 14.9% (15.3 kg), against 2.4% (2.6 kg) on placebo. 86.4% lost at least 5%, and 50.5% lost at least 15%2. |
| Week 72 | 7.2 mg or 2.4 mg | STEP UP, a separate trial in people with obesity and no diabetes: down 18.7% on 7.2 mg and 15.6% on 2.4 mg, against 3.9% on placebo8. |
| Week 104 | Maintenance | STEP 5: down 15.2%, against 2.6% on placebo, with the loss held through the second year5. |
| Week 208 | Maintenance | SELECT, in people with heart disease and overweight or obesity but no diabetes: down 10.2%, against 1.5% on placebo, after four years7. |

The shape is in those numbers: about a tenth of body weight gone by week 20 in the people who reached 2.4 mg3, the loss still building for months after the last step, and a level stretch from about week 60 that held through two years of treatment in STEP 55.
When does appetite change?
Clearly, by week 20. A trial in 72 adults with obesity measured appetite directly. After 20 weeks of semaglutide climbing to 2.4 mg, people ate 35% less at a lunch where they could eat as much as they liked, against placebo. They reported less hunger, more fullness, fewer and weaker food cravings and better control over eating4. The same trial found no evidence of slower stomach emptying at week 20, measured indirectly, so by then a fuller stomach does not explain the drop4.
STEP 1 measured weight, not hunger, so the timing of the first change comes from the people taking it.
Commonly reported: appetite dropping in the first week, with nausea worst in the first days after a dose step; 'food noise', the constant background thoughts about food, going quiet; and portions shrinking without effort.
What side effects come, and when?
The common ones are stomach effects, and they follow the dose steps. The label states they were reported most often during the dose climb1, and in STEP 1 nausea and diarrhoea were typically short-lived, mild to moderate, and eased with time2. In the label's pool of three weight trials of 2.4 mg, run for up to 68 weeks, one of them in people with type 2 diabetes1:
| Side effect | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhoea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Abdominal pain | 20% | 10% |
| Headache | 14% | 10% |
| Fatigue | 11% | 5% |

Few people stopped over them: 4.3% left treatment because of a stomach side effect, against 0.7% on placebo1. What helps in the step-up weeks is ordinary: smaller meals, eating slowly and stopping at the first sign of fullness, steady fluids through the day, and more fibre and water when constipation shows up.
At 7.2 mg the picture is similar with a little more of it. In the label's two 7.2 mg trials: nausea in 39%, against 35% on 2.4 mg and 13% on placebo. One effect rises sharply at that dose: dysaesthesia, altered skin sensations such as tingling or sensitive skin, in 22%, against 6% on 2.4 mg and almost none on placebo1.
When to get help If stomach symptoms turn severe or do not settle, the label's advice is to contact your prescriber1.
What does the label say about a missed dose?
The label's rule for the weekly injection depends on how close the next dose is1:
- Count the days until your next scheduled dose.
- If it is more than two days away, the label says to take the missed dose as soon as possible.
- If it is less than two days away, the label says to skip the missed dose and take the next one on the usual day.
- If you have missed two or more doses in a row, ask your prescriber before your next one: the label restarts the climb at a lower dose, to lower the risk of stomach side effects1.
What is worth tracking week to week?
A weekly drug with a four-week climb is easy to lose count of. These are the records that make each week readable:
- Side effects: note each symptom and how bad it was on the day, so you can see whether nausea gathers around a step-up and fades after it.
- The rest of the week: travel, illness or a missed dose explains a week the scale did not move.
Dose day: PepVault reminds you at the time you set and logs each weekly dose as you took it, so the step you are on stays on record. Set reminders in PepVault
Weight: PepVault's weigh-in log draws your trend, in pounds or kilograms, so a flat week reads against the months around it. Track your weight in PepVault
When does the weight plateau, and what happens if you stop?
Weight loss on semaglutide slows and levels off. In STEP 5, a two-year trial, the average loss plateaued after about week 60 and held for the rest of the study5. In SELECT, weight loss continued over 65 weeks and was sustained for up to four years7.
STEP 4 tested what holds the plateau. After a 20-week run-in up to 2.4 mg, the 803 people who reached that dose were randomly assigned to keep going or switch to placebo. Over the next 48 weeks, those who continued lost a further 7.9%, while those switched to placebo regained 6.9%3. The STEP 1 extension followed 327 people for a year after all treatment, the lifestyle programme included, stopped at week 68. Those who had taken semaglutide regained about two-thirds of the weight they had lost, for a net loss of 5.6% at week 120, against 0.1% on placebo6.
Is semaglutide approved?
Yes. In the US, Wegovy injection is approved, with a reduced-calorie diet and more physical activity, to reduce excess weight and keep it off long term in adults and children 12 and older with obesity, and in adults with overweight and a weight-related condition. It is also approved to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight, and, under an accelerated approval, for MASH, a form of fatty liver disease, in adults with moderate to advanced liver scarring but no cirrhosis1. Wegovy also comes as a once-daily tablet, with its own 30-day steps up to 25 mg1.
Sources
- Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information. DailyMed, revised June 2026. dailymed.nlm.nih.gov
- Wilding JPH et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. PubMed 33567185
- Rubino D et al.; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. PubMed 33755728
- Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021. PubMed 33269530
- Garvey WT et al.; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022. PubMed 36216945
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022. PubMed 35441470
- Ryan DH et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024. PubMed 38740993
- Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025. PubMed 40961952
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.